2.52
+0.09(+3.70%)
Currency In USD
| Previous Close | 2.43 |
| Open | 2.44 |
| Day High | 2.52 |
| Day Low | 2.42 |
| 52-Week High | 9.69 |
| 52-Week Low | 2.31 |
| Volume | 26,239 |
| Average Volume | 425,737 |
| Market Cap | 134.49M |
| PE | -2.65 |
| EPS | -0.95 |
| Moving Average 50 Days | 3.26 |
| Moving Average 200 Days | 5.7 |
| Change | 0.09 |
If you invested $1000 in TScan Therapeutics, Inc. (TCRX) since IPO date, it would be worth $240 as of February 05, 2025 at a share price of $2.52. Whereas If you bought $1000 worth of TScan Therapeutics, Inc. (TCRX) shares 3 years ago, it would be worth $480.92 as of February 05, 2025 at a share price of $2.52.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
GlobeNewswire Inc.
Dec 26, 2024 12:00 PM GMT
WALTHAM, Mass., Dec. 26, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
GlobeNewswire Inc.
Dec 23, 2024 12:00 PM GMT
New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029WALTHAM, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company f
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
GlobeNewswire Inc.
Dec 09, 2024 10:45 PM GMT
To date, event-free survival strongly favors the treatment arm (HR=0.30; p=0.04), and treatment-arm patients trend towards lower probability of relapse (HR=0.28; p=0.14) No dose-limiting toxicities observed and infusions of TSC-100 and TSC-101 were w